73 results about "OA - Osteoarthrosis" patented technology

The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis. In particular, the invention provides the identity of marker proteins whose expressions are correlated with OA, and / or OA progression. Methods and kits are described for using these protein expression profiles in the study and / or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and / or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents.

This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the invention are disclosed.

The invention belongs to the field of nano-enzyme preparation and biological application, and particularly relates to a preparation method and application of M2 type macrophage membrane coated FeMn diatomic nano-enzyme. The preparation method comprises the following steps: by taking nitrogen-doped carbon (BANT) as a carrier, loading Fe and Mn diatoms, synthesizing a novel nano material FeMnDA / BCNT diatomic nano-enzyme, extracting a macrophage membrane from natural macrophages, and coating the FeMnDA / BCNT nano material with the macrophage membrane to finally form M2 type macrophage membrane coated nano-particles, namely [MM] FeMnDA / BCNT. The [MM] FeMnDA / BCNT nano-enzyme prepared by the invention has good biological safety and simulated SOD and CAT enzyme activity, and the expression of inflammatory factors is reduced by removing excessive ROS (reactive oxygen species) in the cartilage cells induced by H2O2, so that the damage of oxidative stress to the cartilage cells is inhibited. The [MM] FeMnDA / BCNT nano-enzyme is not used for treating OA yet, so that a scientific basis is provided for further application and expansion of the diatomic nano-enzyme, and an effective strategy and a new thought are provided for treating osteoarthritis and chronic diseases related to oxidative stress in the future.

The invention provides application of fibroblast activation protein (Fap) as a target in screening drugs for treating osteoarthritis (OA) or inhibiting cartilage injury or osteophyte generation or synovitis. The invention also provides application of an Fap gene as a target in screening drugs for treating OA or inhibiting cartilage injury or osteophyte generation or synovitis. The invention also provides application of a targeted Fap inhibitor in preparation of drugs for treating OA or inhibiting cartilage injury or osteophyte generation or synovitis. The invention also provides application ofosteolectin (Oln) in preparation of drugs for treating OA or inhibiting cartilage injury or osteophyte generation or synovitis. It is found that Fap is highly expressed in synovial membrane of OA, cartilage injury, osteophyte generation, synovitis and cartilage aggregation protein polysaccharide loss of mouse OA can be relieved by inhibiting Fap through genetics and pharmacology, and both an Fapsmall-molecule inhibitor and an endogenous protein inhibitor Oln can treat the OA.

The invention relates to the technical field of medicines, in particular to a construction method and application of a photothermal conversion platform for treating osteoarthritis by regulating synovial macrophage polarization. According to the present invention, the M2 membrane-structured black phosphorus selenium carbon body (M2-BPSeC) photo-thermal nano-platform is innovatively provided, the triple functions of bionic targeting delivery, precise thermal control intervention and immune microenvironment remodeling are integrated, and the excellent synergistic treatment effect is represented in the in-vitro cell model and the OA animal model. The technology breaks through the technical bottleneck that traditional treatment is insufficient in targeting and single in intervention dimension, precise functional coupling of the physical thermal effect and immunoregulation is achieved for the first time, and a brand new strategy of targeting-temperature control-immunity integration is provided for osteoarthritis treatment. The efficient and controllable preparation process and the remarkable multi-dimensional treatment effect open up a new path for cartilage regeneration and immune balance regulation and control.

The invention is directed to methods of improving the therapeutic efficacy of mesenchymal stromal cells (MSCs) for use in treating osteoarthritis (OA), and more specifically to methods of altering levels of certain proteins, phospho-proteins, genes, and / or MSC-secreted cytokines, chemokines, and / or growth factors in order to improve therapeutic efficacy, as well as methods of distinguishing and classifying MSCs as being highly therapeutic or less therapeutic based on levels of certain phospho-proteins and / or MSC-secreted cytokines, chemokines, and / or growth factors and methods of treating a subject having OA with MSCs having improved therapeutic efficacy.

The invention provides electroactive nano short fibers for osteoarthritis cartilage repair and a preparation method thereof, the preparation method comprises the following steps: preparing a nano fiber membrane from a composite material of gelatin, polylactic acid and glycine crystals through electrostatic spinning, and preparing the obtained nano fiber membrane into short fibers; performing freeze drying on the short fibers, and then performing heating treatment to obtain a short fiber stent; the short fiber support is smashed and reacts with graphene oxide, modified graphene oxide short fibers are obtained, and then the modified graphene oxide short fibers are soaked in a mixed solution of alkaline dopamine and phosphatidylcholine for a reaction. The electroactive nano short fiber provided by the invention is low in friction coefficient, the expression quantity of Sirt1 in OA cartilage cells can be remarkably increased under ultrasonic stimulation, the ATP (adenosine triphosphate) productivity can be remarkably improved, release of inflammatory factors and degradation of extracellular matrixes can be inhibited, and meanwhile, a guarantee is provided for updating of a hydrated lubricating layer.

Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and / or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and / or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

The invention discloses preparation and application of a biological material for targeted therapy of osteoarthritis, and the preparation method comprises the following steps: according to a phage screening principle, after phages are combined with cartilage cells, washing off phages which are not combined with the cartilage cells, are not firmly combined with the cartilage cells and are non-specifically combined with the cartilage cells; eluting the specifically bound bacteriophage with glycine acid; after the specific binding bacteriophage is amplified by escherichia coli, screening is carried out by utilizing a bacteriophage display technology and cartilage cells; the preparation method comprises the following steps: preparing a small-size porous microgel loaded drug by adopting a multiple Pickering emulsion template method; and grafting the screened cartilage targeting peptide to the surface of the porous hydrogel microsphere to obtain the HS-SP microsphere. According to the invention, the problem of OA targeting can be effectively solved by adopting a phage display technology, and a drug is precisely targeted and delivered to an OA lesion region; the porous hydrogel microspheres with small particle size are prepared by adopting a multiple Pickering emulsion method, so that the use of a large number of surfactants is avoided, and the efficient loading and release of drugs can be realized.

The invention relates to a diatomic iron-iron site nano-enzyme constructed by relieving oxidative stress and cartilage degeneration and used for targeted osteoarthritis treatment. According to the invention, a nitrogen-doped porous carbon anchored diatomic iron nano enzyme catalyst (Fe2-NCs) with Fe-Fe dimer coordination is developed by using a'subject-object 'strategy. The Fe2-NCs protect cartilage cells from oxidative stress induced apoptosis by modulating ROS and active nitrogen species (RNS) and promoting O2 release. In addition, Fe2-NCs restores mitochondrial function by inhibiting NOX4 expression, improving ATP production, and normalizing COXIV levels. In an in-vivo OA model, the Fe2-NCs can reduce the expression of a pro-inflammatory medium COX-2 through an NF-kappa B signal channel, inhibit the up-regulation of MMP-13 and delay the degradation of type II collagen. The invention provides a new theoretical framework and methodological approach for the treatment of osteoarthritis, and has important clinical and scientific significance.

The invention discloses an application method for revealing RIPK3 as a pathological index of osteoarthritis based on transcriptomics analysis, and belongs to the technical field of molecular biology and genetic engineering.The method comprises the following steps that S1, a Trizol reagent is used for conducting total RNA extraction on an articular cartilage specimen, and the RIN number gt is selected; 7.0, constructing a sequencing library by using the high-quality RNA sample; s2, carrying out quality inspection on the constructed library, and carrying out mRNA sequencing by using an Illumina NovaseqTM6000 sequencer after all the libraries are qualified in quality inspection; s3, carrying out bioinformatics analysis on data generated by high-throughput sequencing; s4, different parts of the cartilage tissue of the OA patient are labeled with RIPK3 through immunofluorescence, it is proved that expression of the RIPK3 in cartilage cells has strong correlation with the pathology of the OA focus, and the feasibility of taking the RIPK3 as a clinical pathology index is proved.

The invention provides an application of MicroRNA-455-3p as an osteoarthritis treatment target and an application of an exosome for overexpression of MicroRNA-455-3p in preparation of a drug for treating osteoarthritis. According to the invention, the MicroRNA-455-3p is used as an osteoarthritis treatment target, and the exosome vector for overexpression of the MicroRNA-455-3p is constructed to carry out early intervention on osteoarthritis so as to realize the purpose of treating OA.

Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (OA) and determining treatment are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including MCP1, IL8, KC, MMP2, MMP3, Apolipoprotein A1, and Apolipoprotein E. Related methods for monitoring OA treatment efficacy, diagnostic reagents, and kits are also described.

The invention belongs to the technical field of biological medicines, and discloses a B cell and cartilage cell senescence targeting osteoarthritis treatment medicine. The invention provides an application of an anti-MIF antibody or an antigen binding fragment thereof as a B cell targeting immunomodulator in osteoarthritis treatment drugs, the anti-MIF antibody or the antigen binding fragment thereof regulates and controls an MIF / HMGB1 / MMP13 signal axis through a neutralization effect with MIF, so that the MIF and B cells are significantly co-localized, expression of HMGB1 in the B cells is promoted, and the osteoarthritis treatment effect is improved. The senescence of B cells is reduced and the B cells are promoted to regulate or repair phenotype transformation so as to destroy chronic inflammatory circulation and diffusion of pathogenic plasma cells, and the expression of MMP13 in joint tissues is reduced so as to maintain the steady state of cartilage tissues; the preparation method has an excellent application prospect in preparation of an OA intra-articular injection drug which realizes rapid anti-inflammatory and long-term cartilage protection effects and can realize a lasting curative effect through low-frequency drug delivery.

The invention relates to the technical field of osteoarthritis drugs, particularly discloses an application of DDX5-K45mRNA in preparation of drugs for treating and / or relieving osteoarthritis, and provides a drug delivery system for targeting chondrocytes at the same time, research finds that when DDX5-K45mRNA is added into the chondrocytes, the drug delivery system can be used for treating and / or relieving osteoarthritis. The medicine can restore DDX5-K45 lactic acid, block NF-kappa B inflammation signals, correct metabolic reprogramming (such as inhibition of abnormal glycolysis), and up-regulate cartilage protection factors such as COL2A1 and the like. The LNP is utilized to efficiently deliver DDX5-K45mRNA to cartilage cells, endogenous lactic acid modification defects are directly supplemented, the cartilage protection function of DDX5 is reconstructed, inflammatory response is inhibited, matrix degradation is reduced, the cartilage steady state is maintained fundamentally, and long-acting and safe OA treatment is achieved.

The invention belongs to the field of biomedicine, and provides application of LDHA as a treatment target of aging-related osteoarthritis. In-vitro cell experiments and animal in-vivo experiments prove that the LDHA inhibitor can inhibit OA progress caused by aging, and targeted inhibition of LDHA in synovial fibroblasts can provide a brand-new treatment strategy for treatment of aging-related osteoarthritis.

The invention belongs to the technical field of biomedicine, and particularly relates to a nucleic acid combination product for detecting SIAH2, a diagnostic kit for osteoarthritis and application of the diagnostic kit. According to the application, the models are established by using machine learning to analyze various cell death modes, and the application finds that in the models of the four cell death modes, the ferroptosis model has the highest diagnosis efficiency on the OA and identifies the corresponding biomarkers. It is found that SIAH2 is used as a biomarker to regulate occurrence and development of OA through cartilage cells, and a new diagnosis and treatment strategy is provided for OA.

The invention relates to an ROS-responsive macrophage-chondrocyte dual-targeting nano-micelle and a preparation method and application thereof, HA capable of targeting and highly expressing CD44 cells is taken as a carrier skeleton, chemical coupling with TK and CUR is carried out in sequence, self-assembly is carried out through intermolecular force to form a stable nano-micelle, and drugs JPH203 and KGN are entrapped at the same time, so that efficient loading and targeting delivery are realized. The HA can be specifically combined with RAW264.7 macrophages and articular cartilage cells for highly expressing a CD44 receptor in an inflammatory state, and is actively delivered in a targeting manner. The ROS response characteristic of TK is utilized, oxidative fracture is carried out in an OA high ROS microenvironment, and micelles are triggered to disintegrate and release drugs accurately. The released JPH203 can inhibit an inflammatory mTOR pathway and effectively resist inflammation, and KGN is beneficial to promoting cartilage cell proliferation and effectively collecting and promoting differentiation of mesenchymal stem cells into cartilage cells, so that in-situ cartilage regeneration is realized, and a more efficient solution with low side effects is provided for osteoarthritis treatment.

Compositions and methods are provided for determining the presence of early-stage osteoarthritis (OA) in an individual by single cell profiling of a blood sample. Through use of machine learning, it is shown that immune cell features associated with OA are present and detectable in the early stages of OA and can be utilized for early detection of the disease.

The present invention discloses an application of a biomarker GSDME. The application includes the use of the biomarker GSDME protein in preparing a kit for diagnosing osteoarthritis OA subtypes, wherein the kit contains a detection reagent and a detection tool for detecting the expression level of the biomarker GSDME protein, and the kit is also used for prognosis assessment of osteoarthritis OA subtypes. The present invention is based on the GSDME protein with high specificity, versatility and reliability as a biomarker, and prepares a kit that can more simply and conveniently detect the GSDME protein, which is easy to use and easy to promote and popularize.

The invention discloses a pathological microenvironment self-driven precise targeting nano-robot as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing an MOF carrier; (2) preparing MOF-coated ISLamp; a CORM-401 compound, and an organic solvent; (3) preparing apoptotic cell membranes; (4) preparing an FH peptide modified apoptosis cell membrane: coupling the FH peptide with a synthetic sequence of FHKHKSPALSPV with DSPE-PEG-NHS, then mixing with apM, carrying out ultrasonic treatment, and carrying out centrifugal purification to obtain FM; (5) preparing a nano robot: MOF (at) ISLamp; the CORM-401 and the FM membrane protein are mixed, asymmetrically wrapped, extruded to pass through a membrane, and centrifuged to obtain the nano-robot. According to the designed self-driven nano-robot integrating the triple functions of self-driving, precise targeting and collaborative treatment, CORM-401-ROS reaction is used for providing active power to break through a synovial membrane barrier, targeted enrichment of core pathological cells is achieved through an engineered cell membrane, the mitochondrial function is synergistically repaired by means of ISL and CO, OA pathological circulation is blocked, and the targeted enrichment of the core pathological cells is achieved. A brand new technical scheme is provided for treatment of osteoarthritis from symptomatic remission to pathological reversion.

The present application relates to the prevention and treatment of osteoarticular diseases, in particular osteoarthritis (OA), by inhibition of acetylcholinesterase (AChE). Specifically, this application provides a disease progression-modifying drug for the treatment of osteoarthritis, i.e., an acetylcholinesterase inhibitor, in particular a dimeric acetylcholinesterase inhibitor. The dimer targets both the enzymatic triad and non-enzymatic peripheral sites of acetylcholinesterase, thereby enhancing protection of articular cartilage and subchondral bone.

Provided herein are compositions containing dehydrated placental tissue particulates, methods of making the compositions and methods for treating various musculoskeletal disorders and other conditions using such compositions, including osteoarthritis (OA), degenerative disc disease, tendonitis, plantar fasciitis, and pain associated therewith.

The application discloses a pathological microenvironment self-driven precise targeted nanorobot and a preparation method and application thereof, and is prepared according to the following steps: (1) preparing a MOF carrier; (2) preparing a MOF@ISL&CORM-401 compound; (3) preparing an apoptotic cell membrane; (4) preparing an FH peptide modified apoptotic cell membrane: coupling FH peptide with a sequence of FHKHKSPALSPV and DSPE-PEG-NHS, mixing with apM under ultrasonic, centrifugal purification, and obtaining FM; (5) preparing a nanorobot: mixing the MOF@ISL&CORM-401 and the membrane protein of FM, asymmetrically wrapping, extruding through the membrane, and centrifugal to obtain the nanorobot. The self-driven nanorobot with the triple functions of self-driving, precise targeting and synergistic treatment is designed, the CORM-401-ROS reaction is utilized to provide active power to break through the synovial membrane barrier, the engineered cell membrane is utilized to realize the targeted enrichment of core pathological cells, the ISL and CO are utilized to repair the mitochondrial function, and the OA pathological cycle is blocked, so that a novel technical scheme is provided for the treatment of osteoarthritis from the symptomatic relief to the pathological reversal.

The invention discloses application of L-glutamine in treatment of osteoarthritis, and relates to the field of biomedicine. The L-Gln is used for treating a rat OA animal model, and the direct curative effect of the L-Gln on OA is systematically evaluated from the aspects of inflammatory response, extracellular matrix secretion, chondrocyte survival, cartilage regeneration and the like. According to the present invention, the L-Gln is used as an anti-osteoarthritis drug, NKILA gene silencing, TGF-beta receptor blocker and other methods are combined to verify that L-Gln can up-regulate NKILA expression through a TGF-beta 1 pathway so as to inhibit NF-kappa B activation, reduce chondrocyte inflammatory injury and promote extracellular matrix secretion and cartilage repair, the L-Gln can be used as a new, cheap and effective osteoarthritis disease improvement drug, pain caused by diseases of patients can be relieved, the damaged cartilage structure is fundamentally improved, and therefore the progress of the diseases is delayed.

A polypeptide that is active against each of a GIP, a GLP-1, and a glucagon receptor is provided. The polypeptides have structural features that result in each of the receptors having activity and extended action time. Also provided are methods for treating diseases and / or conditions such as obesity, long term weight management, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, chronic kidney disease (CKD), osteoarthritis (OA), obesity-associated sleep apnea (OSA), and polycystic ovarian syndrome (PCOS).

The invention belongs to the technical field of biomedicine and particularly relates to application of circular RNA as an osteoarthritis marker. The circular RNA is has_circ_0000423 and has a nucleotide sequence represented by SEQ ID NO: 1. According to the application, researches discover that compared with normal cartilage tissue, hsa_circ_0000423 is of high expression in cartilage tissue of an osteoarthritis sufferer, so that judgment on whether a testee has the high risk of suffering from osteoarthritis or not is contributed through detecting the content of the hsa_circ_0000423, and the significance in clinical auxiliary diagnosis and evaluation on the osteoarthritis is remarkable. Simultaneously, through further researching biological functions of cartilage cells, diagnosis and treatment values of the hsa_circ_0000423 during occurrence and development of OA are discovered, so that a critical theoretical basis and intervention target is provided for diagnosis and treatment on the disease, and thus, the circular RNA has an important potential value and a good application prospect.

The present disclosure refers to novel RNA molecules based on miRNAs which are useful for the treatment of osteoarthritis (OA), by modulating the expression of OA-related genes, as well as combinations and compositions comprising them, and methods related thereto.